1.
Do Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Cause Heart Failure?
by Clifton, Peter, MD, PhD
Clinical therapeutics, 2014, Vol.36 (12), p.2072-2079

2.
Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease
by Myasoedova, Elena
Annals of the rheumatic diseases, 2011-03, Vol.70 (3), p.482-487

3.
The Role of Rheumatoid Arthritis (RA) Flare and Cumulative Burden of RA Severity in the Risk of Cardiovascular Disease
by Myasoedova, Elena Elena
Annals of the rheumatic diseases, 2015-01-30, Vol.75 (3), p.560-565

4.
The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: The Systolic Blood Pressure Intervention Trial (SPRINT)
by Ambrosius, Walter T
Clinical trials (London, England), 2014-10, Vol.11 (5), p.532-546

5.
The Effects of SGLT2 Inhibitors on Cardiovascular and Renal Outcomes in Diabetic Patients: A Systematic Review and Meta-Analysis
by Lo, Kevin Bryan
Cardiorenal medicine, 2020-01, Vol.10 (1), p.1-10

6.
Cardiovascular outcome trials of glucose-lowering medications: an update
by Home, Philip
Diabetologia, 2019-01-03, Vol.62 (3), p.357-369

7.
Cardiovascular Protection by Initial and Subsequent Combination of Antihypertensive Drugs in Daily Life Practice
by Corrao, Giovanni
Hypertension (Dallas, Tex. 1979), 2011-10, Vol.58 (4), p.566-572

8.
A comprehensive review of the FDA-approved labels of diabetes drugs: Indications, safety, and emerging cardiovascular safety data
by Gourgari, Evgenia
Journal of diabetes and its complications, 2017-12, Vol.31 (12), p.1719-1727

9.
Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition
by Vallon, Volker
Diabetologia, 2016-11-22, Vol.60 (2), p.215-225

10.
Global Outcome in Patients with Left Ventricular Assist Devices
by Fendler, Timothy J., MD, MS
The American journal of cardiology, 2017, Vol.119 (7), p.1069-1073

11.
Antihyperglycemic therapies and cardiovascular outcomes in patients with type 2 diabetes mellitus: State of the art and future directions
by Kato, Eri Toda
Trends in cardiovascular medicine, 2021-02, Vol.31 (2), p.101-108

12.
New-onset diabetes in HIV-treated adults: predictors, long-term renal and cardiovascular outcomes
by Putcharoen, Opass
AIDS (London), 2017, Vol.31 (11), p.1535-1543

13.
Subclinical markers of cardiovascular disease predict adverse outcomes in chronic kidney disease patients with normal left ventricular ejection fraction
by Sulemane, Samir
International Journal of Cardiovascular Imaging, 2017-01-24, Vol.33 (5), p.687-698

14.
Living alone and cardiovascular outcomes: a meta-analysis of 11 cohort studies
by Gan, Ting
Psychology, health & medicine, , Vol.ahead-of-print (ahead-of-print), p.1-13

15.
Three-question set from Michigan Neuropathy Screening Instrument adds independent prognostic information on cardiovascular outcomes: Analysis of ALTITUDE trial
by Seferovic, Jelena P
Diabetologia, 2018-03, Vol.61 (3), p.581-588

16.
Cardiovascular Effects of Glucose-lowering Therapies for Type 2 Diabetes: New Drugs in Perspective
by Thompson, Peter L., MD, FRACP, FACC
Clinical therapeutics, 2017, Vol.39 (5), p.1012-1025

17.
Polypills: Common garden variety or precision formulated for improving cardiovascular outcomes: An ongoing challenge
by Thadani, Udho
Trends in cardiovascular medicine, 2022-02-26

18.
Acute Effects of Ambient Particulate Matter on Blood Pressure: Differential Effects Across Urban Communities
by Dvonch, J Timothy
Hypertension (Dallas, Tex. 1979), 2009-05, Vol.53 (5), p.853-859

19.
Regression of electrocardiographic left ventricular hypertrophy or strain is associated with lower incidence of cardiovascular morbidity and mortality in hypertensive patients inde...
by Bang, Casper N., MD, PhD
Journal of electrocardiology, 2014, Vol.47 (5), p.630-635

20.
EMPA-REG OUTCOME: The Cardiologist's Point of View
by Pham, Son V
The American journal of cardiology, 2017-07-01, Vol.120 (1S), p.S53
